Your browser doesn't support javascript.
loading
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].
Hartlapp, I; Valta-Seufzer, D; Siveke, J T; Algül, H; Goekkurt, E; Siegler, G; Martens, U M; Waldschmidt, D; Pelzer, U; Fuchs, M; Kullmann, F; Boeck, S; Ettrich, T J; Held, S; Keller, R; Anger, F; Germer, C T; Stang, A; Kimmel, B; Heinemann, V; Kunzmann, V.
  • Hartlapp I; Department of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
  • Valta-Seufzer D; Department of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
  • Siveke JT; Department of Medical Oncology, Bridge Institute of Experimental Tumor Therapy, University Medicine Essen, Essen; Division of Solid Tumor Translational Oncology (DKTK Partner Site Essen, DKFZ Heidelberg), West German Cancer Center, University Medicine Essen, Essen.
  • Algül H; Comprehensive Cancer Center München, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Bavaria, Germany.
  • Goekkurt E; Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg and University Cancer Center Hamburg (UCCH), Hamburg, Germany.
  • Siegler G; Department of Internal Medicine 5, Hematology and Medical Oncology, Paracelsus Medical University, Nürnberg.
  • Martens UM; Department of Internal Medicine III, SLK-Clinics Heilbronn GmbH, Heilbronn.
  • Waldschmidt D; Department of Gastroenterology and Hepatology, University Hospital Cologne, Cologne.
  • Pelzer U; Division of Oncology and Hematology, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin.
  • Fuchs M; Clinic for Gastroenterology, Hepatology and GI-Oncology, München Klinik Bogenhausen, Munich.
  • Kullmann F; Department of Internal Medicine I, Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden.
  • Boeck S; Department of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilians University-Grosshadern, Munich.
  • Ettrich TJ; Department of Internal Medicine I, Ulm University Hospital, Ulm.
  • Held S; Department of Biometrics, ClinAssess GmbH, Leverkusen.
  • Keller R; Clinical Research, AIO Studien gGmbH, Berlin.
  • Anger F; Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery and Comprehensive Cancer Center Mainfranken Würzburg, University Hospital Würzburg, Würzburg.
  • Germer CT; Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery and Comprehensive Cancer Center Mainfranken Würzburg, University Hospital Würzburg, Würzburg.
  • Stang A; Department of Haematology, Oncology and Palliative Care Medicine, Asklepios Hospital Barmbek, Hamburg, Germany.
  • Kimmel B; Department of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
  • Heinemann V; Department of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilians University-Grosshadern, Munich.
  • Kunzmann V; Department of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg. Electronic address: kunzmann_v@ukw.de.
ESMO Open ; 9(5): 103463, 2024 May.
Article en En | MEDLINE | ID: mdl-38703429
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article